Doris A. Taylor

Doris A. Taylor

Auto-generated profile, based on publicly available information

Doris A. Taylor

Regenerative Medicine Research, Texas Heart Institute, Houston, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Acta Biomaterialia
Verified
Journal Article
Closed access
DTDoris A. Taylor
Doris A. Taylor
LSLuiz C. Sampaio
Luiz C. Sampaio
ZFZannatul Ferdous
Zannatul Ferdous
AGAndrea S. Gobin
Andrea S. Gobin
LTLakeshia J. Taite
Lakeshia J. Taite

1 August 2015 in Biomaterials
Verified
Journal Article
Closed access
PSPedro L. Sánchez
Pedro L. Sánchez
MSMaria Eugenia Fernandez Santos
Maria Eugenia Fernandez Santos
SCSalvatore Costanza
Salvatore Costanza
ACAndreu M. Climent
Andreu M. Climent
IMIsabel Moscoso
Isabel Moscoso
FFFrancisco Fernández-Avilés
Francisco Fernández-Avilés

27 February 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MRMatthew J. Robertson
Matthew J. Robertson
JDJessica L. Dries-Devlin
Jessica L. Dries-Devlin
SKStefan M. Kren
Stefan M. Kren
JBJana S. Burchfield
Jana S. Burchfield
DTDoris A. Taylor
Doris A. Taylor
Perfusion decellularization of cadaveric hearts removes cells and generates a cell-free extracellular matrix scaffold containing acellular vascular conduits, which are theoretically sufficient to perfuse and support tissue-engineered heart constructs. However, after transplantation, these acellular vascular conduits clot, even with anti-coagulation. Here, our objective was to create a less thrombogenic scaffold and improve recellularized-left ventricular contractility by re-lining vascular conduits of a decellularized rat heart with rat aortic endothelial cells (RAECs). We used three strategies to recellularize perfusion-decellularized rat heart vasculature with RAECs: retrograde aortic infusion, brachiocephalic artery (BA) infusion, or a combination of inferior vena cava (IVC) plus BA infusion. The re-endothelialized scaffolds were maintained under vascular flow in vitro for 7 days, and then cell morphology, location, and viability were examined. Thrombogenicity of the scaffold was assessed in vitro and in vivo. Both BA and IVC+BA cell delivery resulted in a whole heart distribution of RAECs that proliferated, retained an endothelial phenotype, and expressed endothelial nitric oxide synthase and von Willebrand factor. Infusing RAECs via the combination IVC+BA method increased scaffold cellularity and the number of vessels that were lined with endothelial cells; re-endothelialization by using BA or IVC+BA cell delivery significantly reduced in vitro thrombogenicity. In vivo, both acellular and re-endothelialized scaffolds recruited non-immune host cells into the organ parenchyma and vasculature. Finally, re-endothelialization before recellularization of the left ventricular wall with neonatal cardiac cells enhanced construct contractility. This is the first study to re-endothelialize whole decellularized hearts throughout both arterial and venous beds and cavities by using arterial and venous delivery. The combination (IVC+BA) delivery strategy results in enhanced scaffold vessel re-endothelialization compared to single-route strategies. Re-endothelialization reduced scaffold thrombogencity and improved contractility of left ventricular-recellularized constructs. Thus, vessel and cavity re-endothelialization creates superior vascularized scaffolds for use in whole-organ recellularization applications.

1 July 2017 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
YByaron barac
yaron barac
FEFabian Emrich
Fabian Emrich
EKEfrat Krutzwakd-Josefson
Efrat Krutzwakd-Josefson
SSSonja Schrepfer
Sonja Schrepfer
LSLuiz C. Sampaio
Luiz C. Sampaio
DTDoris A. Taylor
Doris A. Taylor

1 February 2017 in Acta Biomaterialia
Verified
Journal Article
Closed access
PLPo-Feng Lee
Po-Feng Lee
ECEric Chau
Eric Chau
RCRafael Cabello
Rafael Cabello
AYAlvin T. Yeh
Alvin T. Yeh
LSLuiz C. Sampaio
Luiz C. Sampaio
DTDoris A. Taylor
Doris A. Taylor

1 November 2014 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
DTD. A. Taylor
D. A. Taylor
LSL. C. Sampaio
L. C. Sampaio
AGA. Gobin
A. Gobin
Cardiovascular disease (CVD) is the number one cause of death in the United States. However, few treatments for CVD provide a means to regain full cardiac function with no long-term side effects. Novel tissue-engineered products may provide a way to overcome the limitations of current CVD therapies by replacing injured myocardium with functioning tissue or by inducing more constructive forms of endogenous repair. In this review, we discuss some of the factors that should be considered in the development of tissue-engineered products, and we review the methods currently being investigated to generate more effective heart valves, cardiac patches and whole hearts.